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Critical role of reactive oxygen species (ROS) for
synergistic enhancement of apoptosis by vemurafenib
and the potassium channel inhibitor TRAM-34 in
melanoma cells
Daniel Bauer1,2, Felix Werth1,3, Ha An Nguyen1,2, Felix Kiecker1 and Jürgen Eberle*,1
Inhibition of MAP kinase pathways by selective BRAF inhibitors, such as vemurafenib and dabrafenib, have evolved as key
therapies of BRAF-mutated melanoma. However, tumor relapse and therapy resistance have remained as major problems, which
may be addressed by combination with other pathway inhibitors. Here we identified the potassium channel inhibitor TRAM-34 as
highly effective in combination with vemurafenib. Thus apoptosis was significantly enhanced and cell viability was decreased. The
combination vemurafenib/TRAM-34 was also effective in vemurafenib-resistant cells, suggesting that acquired resistance may be
overcome. Vemurafenib decreased ERK phosphorylation, suppressed antiapoptotic Mcl-1 and enhanced proapoptotic Puma and
Bim. The combination resulted in enhancement of proapoptotic pathways as caspase-3 and loss of mitochondrial membrane
potential. Indicating a special mechanism of vemurafenib-induced apoptosis, we found strong enhancement of intracellular ROS
levels already at 1 h of treatment. The critical role of ROS was demonstrated by the antioxidant vitamin E (α-tocopherol), which
decreased intracellular ROS as well as apoptosis. Also caspase activation and loss of mitochondrial membrane potential were
suppressed, proving ROS as an upstream effect. Thus ROS represents an initial and independent apoptosis pathway in melanoma
cells that is of particular importance for vemurafenib and its combination with TRAM-34.
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For decades, melanoma remained a deadly disease lacking
an effective therapy in the metastatic stage. The situation
changedwith the identification of activating BRAFmutations in
about one-half of cutaneous melanomas.1 Selective BRAF
inhibitors (vemurafenib, dabrafenib) as well as inhibitors of
the downstream MAP kinase MEK (trametinib, cobimetinib)
have now been approved for therapy of BRAF-mutated
melanomas.2,3 Especially, combinations of BRAF and MEK
inhibitors have shown substantial benefit for patients with
regard to significant prolongation of overall survival.4,5 The
situation may even further improve with combinations of
immune checkpoint inhibitors, such as anti-CTLA4 and
anti-PD1.6 Nevertheless, tumor relapse and therapy resis-
tance are still frequent and often follow within only a few
months.7 Thus, although present clinical results are highly
encouraging, further improvements and particularly new, even
more effective combinationswill be needed to finally overcome
melanoma mortality.
Different cellular mechanisms may contribute to therapy
resistance of cancer,8 of which apoptosis deficiency may be
considered as the major cause. This is explained by the fact
that elimination of cancer cells through proapoptotic programs
represents the common end path of most anticancer
strategies. For example, different chemotherapeutic drugs
cause cellular or DNA damage, which induces cell-intrinsic
proapoptotic pathways; and also BRAF inhibitors induce
apoptosis or sensitize for proapoptotic programs.9–11
Two major apoptosis pathways have been described that
are initiated by the interaction of death ligands with death
receptors (extrinsic pathway) and by cellular or DNA damage
(intrinsic pathway), respectively. Downstream, caspase
cascades are activated consisting of initiator and effector
caspases, such as caspase-3.12 In several tumor cells,
including melanoma cells, efficient apoptosis induction needs
proapoptotic mitochondrial activation.9,13 Mitochondrial con-
tribution to apoptosis is closely related to a loss of mitochon-
drial membrane potential (MMP) and release of proapoptotic,
mitochondrial factors. This pathway is critically controlled by
the family of proapoptotic and antiapoptotic Bcl-2 proteins.14
Besides the well-established pathways, there is increasing
evidence for alternative and possibly supplementary path-
ways. Thus reactive oxygen species (ROS) may initiate
independent apoptosis programs.15,16 In melanoma cells, we
have previously found enhanced ROS levels in response to an
iron-containing nucleoside analog and to the phospoinositol-3
kinase inhibitor wortmannin.17,18 Elevation of ROSwas proven
as critical for apoptosis induction, as apoptosis was prevented
by the ROS scavenger α-tocopherol.
Membrane ion channels, which serve fundamental cellular
functions, represent additional, promising tumor targets. Thus
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Ca2+-dependent potassium channels contribute to cyto-
plasma membrane hyperpolarization facilitating Ca2+ entry, a
prerequisite for cell proliferation. Overexpression of the family
member KCa3.1 (IK1) was related to aberrant cell proliferation
of different tumor cells, including melanoma.19,20 TRAM-34
has been established as a selective KCa3.1 inhibitor, which
avoids side effects of some other channel inhibitors, such as
hepatotoxicity.21,22 We have previously shown that TRAM-34
can act as apoptosis enhancer in melanoma cells when
combined with the death ligand TRAIL (TNF-related
apoptosis-inducing ligand).23 Here we demonstrate that
apoptosis induction by vemurafenib in melanoma cells is
strongly enhanced by TRAM-34. Unraveling the pathway
identified ROS generation as a general factor in vemurafenib-
induced apoptosis, which appears of particular importance for
the combination with TRAM-34.
Results
For identifying suitable combination partners, which may
enhance the antitumor activities of vemurafenib, a screening
with several pathway inhibitors and apoptosis agonists was
performed (data not shown). Synergistic enhancement of
apoptosis in the combination of vemurafenib and TRAIL,
which had been described previously,11 served as positive
control. Of the different effectors tested, TRAM-34, an inhibitor
of the potassium channel KCa3.1, appeared of particular
value. Although it did not trigger apoptosis by itself, TRAM-34
strongly enhanced and accelerated vemurafenib-induced
proapoptotic effects. Vemurafenib was applied in a standard
concentration of 30 μM as well as in two reduced concentra-
tions of 3 and 10 μM. TRAM-34 further enhanced apoptosis at
all tested concentrations. Thus apoptotic rates were stepwise
increased when raising the concentration of TRAM-34 from 0
to 25 to 50 μM. For example, at 48 h, the numbers of apoptotic
cells increased from 12% to 23% to 33% for 3 μMvemurafenib,
from 18% to 33% to 41% for 10 μM vemurafenib and from 49%
to 79% to 86% for 30 μM vemurafenib (Figure 1a). These
effects were clearly more than additive, particularly as there
was only limited proapoptotic effect of TRAM-34 alone
(Figure 1b).
In order to generalize the findings on enhanced apoptosis,
two more melanoma cell lines (Mel-HO and Mel-2a) were
investigated. All three cell lines carry BRAF mutations, but
whereas A-375 and Mel-HO were responsive to vemurafenib
single treatment, Mel-2a revealed pronounced resistance.
Nevertheless, comparable enhancement of apoptosis was
seen in all three melanoma cell lines for the combination of
30 μM vemurafenib+50 μM TRAM-34 versus vemurafenib
alone. Thus, in Mel-HO, apoptosis rates increased at 48 h
from 27% to 62% by the combination with TRAM-34. In
vemurafenib-resistant Mel-2a, apoptosis rates raised from
o5% at 48 h up to 40±2% (Figure 1c). This suggests that
the combination effect reported here may be representative
for melanoma cells, even in case of intrinsic vemurafenib
resistance.
To further prove the issue of vemurafenib resistance,
another model was established in A-375. Cells were cultured
with successively increasing concentrations of vemurafenib
up to 10 μM within a period of 4 weeks. The selected cells
showed continuous growth despite vemurafenib and revealed
no apoptotic response to 10 μM. Nevertheless, these cells
were significantly responsive to the combined treatment of
vemurafenib/TRAM-34. In response to 10 μM vemurafenib
+TRAM-34, apoptosis was induced up to 19% and 58% at 24
and 48 h, respectively. Similarly, apoptosis induced by 30 μM
vemurafenib was enhanced (Figure 1d). Thus both intrinsic
resistance (Mel-2a) and induced vemurafenib resistance
(A-375-VemR) were overcome in these models.
Enhanced apoptosiswent along with a reciprocal loss of cell
viability, as determined by calcein staining and subsequent
flow cytometry. At all vemurafenib concentrations used (3, 10,
30 μM), TRAM-34 further decreased cell viability. Thus, at
48 h, the numbers of viable cells in response to vemurafenib
stepwise further decreased when raising TRAM-34 concen-
tration from 0 to 25 to 50 μM. Values decreased from 73%
to 68% to 39% (Vem 3 μM), from 69% to 42% to 17% (Vem
10 μM) and from 31% to 2% to 0.5% (Vem 30 μM) (Figure 2a).
Also concerning cell viability, the combination effects were
far more than additive (Figure 2b).
In order to distinguish between direct cytotoxic effects (cell
lysis) and apoptosis induction, release of lactate dehydrogen-
ase (LDH) into the cell culture supernatant was quantified by
an enzymatic assay at 24 and 48 h. In contrast to induced
apoptosis, LDH activity in cell culture supernatant remained at
a low level, thus indicating that cells were not lysed up to 24 h.
Only at 48 h of combination treatment, LDH levelswere slightly
enhanced by 2.3-fold as compared to control cells, which may
be explained by secondary cell lysis following apoptosis in cell
culture (Figure 2c). Complete cell rounding and detachment,
characteristic of apoptotic cells, were seen already at 24 h of
combination treatment (Figure 2d), andmonitoring attachment
of cells in real time (xCELLigence system) confirmed that both
single treatments resulted in only intermediate effects, while
the combination of TRAM-34 and vemurafenib resulted in
complete cell detachment (Figure 2e).
Thus apoptosis appeared as the dominant effect of
the combination vemurafenib/TRAM-34 demanding an
unravelling of the pathways involved. As expected, vemur-
afenib almost completely abolished ERK phosphorylation.
Total ERK was also downregulated at 48 h of combination
treatment, which may be explained by strong apoptosis
induction at this time. In contrast, TRAM-34 remained without
effect on ERK. For 30 μM vemurafenib applied, only little
rebound ERK activation was seen at 48 h, indicating a largely
sustained effect (Figure 3a).
BRAF inhibition in A-375 was correlated to downregulation
of the antiapoptotic Bcl-2-related protein Mcl-1 as well as to
upregulation of the proapoptotic BH3 domain-only proteins
Puma and Bim (24 kDa, isoform EL), as also shown
previously.10 The finding that Puma was downregulated again
after 48 h is explained by strongly induced apoptosis, which
may lead to degradation of many proteins. Of the other
apoptosis regulators investigated by Western blotting, anti-
apoptotic Bcl-2 and the proapoptotic transcription factor
p53 were not regulated by TRAM-34 or vemurafenib. But
antiapoptotic XIAP as well as proapoptotic Bax were down-
regulated at 48 h of combination treatment in course of
massive apoptosis induction (Figure 3a). Thus Bcl-2 proteins
appear of particular note for vemurafenib activity, but there
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Figure 1 (a) Apoptosis induction is shown in the melanoma cell line A-375 at 24 and 48 h of treatment with vemurafenib (Vem; 3, 10, 30 μM) and TRAM-34 (TRAM; 25, 50,
100 μM). Apoptotic effects with the concentrations of 30 μM Vem and 50 μM TRAM, used for most subsequent experiments, have been reproduced multiple times (43 × ).
Apoptosis values correspond to cells with a less DNA content than cells in G1 phase, which is due to DNA fragmentation (sub-G1). Examples are given on the right side. Cell
populations in G1, G2 and S-phase as well as sub-G1 cells are indicated. (b) For three conditions (24 h, TRAM-24, 25 μM and 50 μM; 48 h, 50 μM TRAM-24), calculated additive
effects on apoptosis (diamond symbols) are directly compared with experimentally determined combination effects (circle symbols, corresponding to panel (a)). Calculated
additive effects result from direct addition of apoptosis by vemurafenib and apoptosis by TRAM-34. For further comparison, apoptosis by vemurafenib alone (3, 10, 30 μM) is
shown (square symbols). (c) Melanoma cell lines Mel-HO and Mel-2a were treated with selected concentrations of Vem (30 μM) and TRAM (50 μM). (d) Combinations of TRAM
(50 μM) and Vem (10, 30 μM) were used for treatment of an A-375 cell population selected for vemurafenib resistance. All experiments have been performed with triplicate values,
and at least two independent experiments for panels (c and d) revealed highly comparable effects
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Figure 2 (a) Cell viability was determined by calcein staining in A-375 cells at 24 and 48 h in response to vemurafenib (Vem; 3, 10, 30 μM) and TRAM-34 (TRAM; 25, 50,
100 μM). Effects on cell viability with the selected concentrations of 30 μM Vem and 50 μM TRAM have been reproduced at least two times. Examples of calcein-stained cells are
given on the right side. Non-viable and viable cell populations are indicated. (b) For three conditions (24 h, TRAM-34 25 μM and 50 μM; 48 h, TRAM-24 50 μM), calculated
additive effects on viability (diamond symbols) are directly compared with experimentally determined combination effects (circle symbols, corresponding to panel (a)). Calculated
additive effects result from addition of the negative effects by vemurafenib and TRAM-34. For further comparison, effects by vemurafenib alone (3, 10, 30 μM) is shown (square
symbols). (c) Relative cytotoxicity was determined by quantification of released LDH. Cells completely lysed by triton-x100 treatment (Triton) served as positive controls (triplicate
values,42 independent experiments). (d) Rounded and detached cells were characteristic of combination treatment at 24 h. (e) Adherent cells corresponding to cell proliferation
were determined in real time by the xCELLigence system (triplicate values). Time of treatment is indicated by an arrow
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was no indication that altered expression of Bcl-2 proteins was
also critical for the combination effects seen here with
TRAM-34.
Significant activation of the major effector caspase-3 upon
combination treatment (24 and 48 h) was seen by its
characteristic cleavage products of 17 and 15 kDa, suggesting
a contribution of caspase-mediated pathways. Nevertheless,
caspase activation appeared as not complete, seen by still
high levels of procaspase-3 (Figure 3a). The role of caspases
was further addressed by using the pancaspase inhibitor
QVD-OPh. Pretreatment of A-375 with QVD-OPh (10 μM) for
1 h resulted in significant but not complete reduction of
apoptosis by vemurafenib alone (9%→3%) as well as by the
combination (47%→ 13%). Similarly, cell viability was partly
restored (16%→33%; Figure 3b).
Proapoptotic and antiapoptotic Bcl-2 proteins control
mitochondrial apoptosis pathways, for which loss of the
MMP represents a critical step. Whereas in A-375, TRAM-34
and vemurafenib as single treatments remained without
significant effect on MMP at 4 and 24 h, the combination
resulted in a complete loss of MMP at 24 h (490%), indicating
full activation of mitochondrial apoptosis pathways at this time
(Figure 3c). Similarly, 60% cells with low MMP were obtained
in Mel-2a at 24 h. Only here, cells also showed response at 4 h
(Figure 3d).
The decisive roles of Bcl-2 proteins and mitochondrial
pathways were further confirmed by the results of Bcl-2
overexpression. Thus Vem/TRAM-induced apoptosis was
completely prevented in a stably Bcl-2-overexpressing A-375
cell line (A375-Bcl-2), as compared with a mock-transfected
cell clone (A375-pIRES; Figure 3e). Both cell clones had been
previously established and characterized.13
Despite the obvious significance of lost MMP at 24 h, it
should be considered at least in A-375 as a delayed effect, as
less evident at 4 h (Figure 3c). Thus we looked for more initial
effects. By this, we identified the generation of ROS as an
immediate early event, already visible at 1 h of treatment. Thus
ROS levels were consistently upregulated by vemurafenib
single treatment raising from 27% of cells with high ROS at 1 h
to 49% cells at 24 h. This effect further increased with the
combination treatment resulting in 48% cells with high ROS at
1 h and 72% cells at 4 h (Figure 4a). Thus the whole cell
population shifted toward higher ROS levels upon treatment
(Figure 4b). The reproducible finding that ROS levels upon
combination treatment were again downregulated at 24 h
underlined the transient appearance of ROS, which was thus
not a consequence of induced apoptosis. In parallel, we
obtained ROS generation in Mel-2a by vemurafenib at 2 h,
which was, with 19±2%, however, less than in vemurafenib-
sensitive A-375. Nevertheless, upon combination treatment,
ROS levels were raised up to 42± 4% (Figure 4c).
To prove the significance of ROS production, we performed
experiments with the ROS scavenger α-tocopherol (VitE). In
fact, pretreating A-375 cells for 1 h with 1 mM VitE reduced
ROS levels upon vemurafenib and combination treatment by
almost twofold (Figure 5a). This resulted in a concomitant
twofold reduction of apoptosis (Figure 5b) and largely
recovered cell viability (Figure 5c). Thus ROS produced by
vemurafenib appeared as largely responsible for enhanced
apoptosis upon combination treatment. Further demonstrating
its signaling effect, caspase-3 activation by vemurafenib/
TRAM was completely abolished by vitamin E, just as it was
abolished by the pancaspase inhibitor QVD-OPh (Figure 6a).
Also MMPwas largely restored by vitamin E, locating also loss
of MMP as downstream of ROS in the signaling cascade
(Figure 6b).
Discussion
The development of selective inhibitors for BRAF and MEK as
well as immune checkpoint inhibitors such as anti-CTLA4 and
anti-PD1 have revolutionized melanoma therapy in the past
years leading to significant improvements for melanoma
patients.2,3,6,7 To further overcome therapy resistance and
tumor relapse, combination therapies are of principle value as
actually being demonstrated by combinations of BRAF and
MEK inhibitors.4,5 Also, combinations of targeted therapy and
immune checkpoint inhibitors are considered.24,25 Besides,
many other combinations have been tested in melanoma
experimental models. Enhanced efficiency was described for
combinations of vemurafenib with different strategies, for
example, with cyclin-dependent kinase 4 and 6 inhibitor,26 with
inhibitors of epigenetic regulators27 or radiotherapy.28 Often
toxicity is a limiting factor for in vivo use. Given a high number
of possible targets in cancer cells, the repertoire of, in
principle, suitable combination partners will grow tremen-
dously in near future, giving much hope for further improve-
ment of cancer therapies.
Inhibitors of membrane channels expressed in cancer cells
represent additional, promising candidates that are still
awaiting their full exploration. Potassium channels have critical
roles in a wide variety of physiological processes. The group of
Ca2+-dependent K+ channels contributes to cytoplasmic
membrane hyperpolarization thus facilitating Ca2+ entry, a
prerequisite for cell proliferation.19 The family member KCa3.1
is inhibited by clotrimazole, which itself is, however, not
suitable for systemic application as hepatotoxicity results from
non-specific effects on cytochrome P450. In contrast, the
clotrimazole analogs TRAM-34 and ICA-17043 are more
selective for KCa3.1 and lack P450-inhibitory activity.21,29
Specificity of TRAM-34 was also proven in KCa3.1-negative
HEK-293 cells, which did not respond, whereas responsive-
ness was recovered in KCa3.1-transfected cells.23
Knockoutmice for KCa3.1 are viable and ICA-17043waswell
tolerated in a clinical trial, showing almost no adverse
effects.29,30 Thus KCa3.1 may not be required for steady-
state physiological balance but may be upregulated in disease
situations. It may have critical roles in aberrant cell proliferation
and cytokine synthesis in cancer and autoimmune disease.29
Blockade of KCa3.1 frequently results in G0/G1 cell cycle arrest
and inhibitory effects on cytokine synthesis, which may be
caused by suppressed calcium inflow.31,32 KCa3.1 mRNA is
overexpressed in different cancer cell lines, for example, of
glioblastoma, pancreatic carcinoma, breast carcinoma and
prostate carcinoma.20,29 In a series of melanoma cell lines,
mRNA and protein expression was shown, suggesting KCa3.1
expression as characteristic for melanoma.23 Also in nudemice,
KCa3.1 inhibition by clotrimazole inhibited melanoma growth.31
Antitumor effects of KCa3.1 inhibition were correlated to
suppression of cell proliferation and migration in breast cancer,
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Figure 3 (a) Protein expression was determined by Western blotting in A-375 cells at 24 and 48 h in response to treatment with 30 μM vemurafenib (Vem), 50 μM TRAM-34
(TRAM) and the combination (Combi). Expression was compared with non-treated cells (Ctr). Proteins analyzed: phosphorylated ERK (pERK), total ERK (ERK), antiapoptotic
factors (Mcl-1, Bcl-2, XIAP), proapoptotic factors (Puma, BimEL, Bax, p53), and caspase-3 (proform, 35 kDa; active, cleaved forms, 15 and 17 kDa). Each determination was
repeated with a second independent series of protein extracts, which showed highly comparable results. (b) The significance of caspase activation was proven by additional
treatment with the pan-caspase inhibitor QVD-OPh (QVD, 10 μM). (c and d) Loss of MMP was determined by the potential-sensitive dye TMRM+ at 4 and 24 h of treatment in
A-375 and Mel-2a. Examples, as determined by flow cytometry, are shown in the right panels. Cells with low MMP are indicated. (e) Apoptosis was determined in a Bcl-2-
overexpressing A-375 cell clone (A375-Bcl-2). It was compared with a sensitive mock/plasmid-transfected A-375 cell clone (A375-pIRES). (b–d) All determinations were carried
out in triplicates; asterisks indicate statistical significance
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endometrial carcinoma and hepatocellular carcinoma cells.33–35
In combinations, it increased the sensitivity of glioblastoma cells
for radiotherapy36 and of glioma cells for temozolomide.37 In
most instances, KCa3.1 blockers were cytostatic rather than
cytotoxic or proapoptotic,33,38 which may limit their use as
monotherapy but may encourage for combination with pro-
apoptotic agents. This was also seen in melanoma cells,
namely, KCa3.1 inhibition by TRAM-34 decreased cell
proliferation without directly affecting apoptosis, but it strongly
sensitized melanoma cell lines for TRAIL-induced apoptosis.23
Here we prove TRAM-34 as a suitable combination partner
for vemurafenib. Upon combination, apoptosis was strongly
enhanced and even vemurafenib-resistant cells could be
targeted. Cell viability and overall cell proliferation were
completely abolished, whereas direct cytotoxc effects (cell
lysis) remained at a low level. Concerning the proapoptotic
mechanisms, activation of caspase-3, the mitochondrial
pathway and elevation of ROS levels were shown. Enhanced
apoptosis and loss of cell viability were evident not only for the
standard concentration of 30 μM vemurafenib but also for
reduced concentrations, not indicating a threshold for mutual
enhancement. Also, the combination effect appeared as
representative for melanoma cells as seen in 3/3 BRAF-
mutated melanoma cell lines.
Whereas caspase cascades and proapoptotic mitochon-
drial activation represent standard pathways in apoptosis
control, the regulation of apoptosis byROS is less understood.
The significance of ROS for apoptosis induction has been
Figure 4 (a) Intracellular levels of ROS were determined in A-375 at 1, 2, 4 and 24 h of treatment with 30 μM vemurafenib (Vem), 50 μM TRAM-34 (TRAM) and the
combination. The assay is based on staining with the ROS-sensitive dye H2DCFDA and subsequent flow cytometry. (b) Examples of treated cells versus controls are given. H2O2-
treated cells served as positive control; cells with high ROS are indicated. The experiment was performed in triplicates; at 2 and 4 h, at least two independent experiments
revealed highly comparable results. (c) Increased ROS levels are shown in Mel-2a at 2 h in response to vemurafenib (30 μM), TRAM-34 and the combination. Examples are
shown on the right side (triplicate determinations, two experiments)
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proven by us previously,17,18 and increased ROS levels in
response to vemurafenib were also reported.39,40 Here we
prove ROS as a major factor in vemurafenib-induced
apoptosis, in particular, in its combination with TRAM-34. This
was shown by the ROS scavenger α-tocopherol, which
strongly diminished apoptosis induction and partly restored
cell viability. ROS was also upstream of other signaling steps,
as it appeared already within 1 h, and α-tocopherol blocked
both caspase activation and loss of MMP. As a possible origin
of ROS, the endoplasmatic reticulum (ER) may be considered,
as ER stress has already been linked to vemurafenib-induced
apoptosis.10
In conclusion, these data shed more light on a frequently
used but not completely understood melanoma therapy. ROS
represents an initial and independent apoptosis pathway that
is of particular importance for vemurafenib and its combination
with TRAM-34 in melanoma cells. Better understanding may
be helpful for further improving targeted therapy in melanoma.
Materials and Methods
Cell culture. Three BRAF mutated human melanoma cell lines were used in the
present study: A-375,41 Mel-HO42 and Mel-2a.43 A-375 subclones had been
established previously by stable transfection of a pIRES-Bcl-2 plasmid for Bcl-2
overexpression (A375-Bcl-2) or by transfection of an empty pIRES plasmid (A375-
pIRES, mock control).13 Cells were cultured at 37 °C, 5% CO2 with DMEM (4.5 g/l
glucose; GIBCO, Invitrogen, Karlsruhe, Germany) supplemented with 10% FCS and
antibiotics (Biochrom, Berlin, Germany). For analyses, 5 × 104 and 2 × 105 cells
were seeded in 24- and 6-well plates, respectively.
The selective BRAF (V600E) inhibitor vemurafenib/PLX4032 (Selleck Chemicals,
Houston, TX, USA) was used at a standard concentration of 30 μM. This
concentration theoretically corresponds to doses applied in patients (960 mg/12 h;
MW= 490 g/mol). In several experiments, also reduced concentrations (3 and
10 μM) were included. TRAM-34, a selective inhibitor of the Ca2+-dependent
potassium channel KCa3.1 (IK1), has been kindly provided by Dr. Heike Wulff,
University of California, Department of Pharmacology, Davis, CA, USA.21 According
to a previous study in melanoma cells,23 TRAM-34 was used at a standard
concentration of 50 μM. For caspase inhibition, the pan-caspase inhibitor QVD-OPh
(Sigma-Aldrich, Taufkirchen, Germany) was used at 10 μM, 1 h before other
treatments started.
Figure 5 (a) Intracellular ROS levels were determined in A-375 at 4 h of treatment with 30 μM vemurafenib (Vem), 50 μM TRAM-34 (TRAM), the ROS scavenger vitamin E
(VitE; α-tocopherol; 1 mM) and combinations. Examples on the right side demonstrate reduction of high ROS levels through VitE. (b and c) Induction of apoptosis (b) and loss of
cell viability (c) were determined at 48 h in response to Vem (30 μM), TRAM (50 μM) and VitE (1 mM). All experiments were performed in triplicates, and at least two independent
experiments showed highly comparable results; asterisks indicate statistical significance
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Cell cycle analysis, apoptosis, cytotoxicity, cell viability, cell
proliferation and adhesion. Quantification of apoptosis was performed by
cell cycle analyses.44 Trypsinized cells were lysed in hypotonic buffer, and isolated
nuclei were stained for 1 h with 40 mg/ml propidium iodide (Sigma-Aldrich). Cell
fractions in G1, G2 and S-phase as well as sub-G1 cells were quantified by
flow cytometry at FL3A with a FACS Calibur (BD Bioscience, Bedford, MA, USA).
Owing to the washing out of small DNA fragments, nuclei with less DNA than in
G1 (sub-G1) correspond to apoptotic cells with fragmented DNA.
Direct cytotoxicity (cell lysis) was determined by quantifying released LDH activity
in cell supernatants by an LDH activity enzymatic assay (Roche Diagnostics,
Penzberg, Germany), which was quantified in an ELISA reader later.
Cell viability was determined by staining cells with calcein-AM (PromoCell,
Heidelberg, Germany), which is converted in viable cells to green-fluorescent calcein
by intracellular esterases. Cells, grown and treated in 24-well plates, were trypsinized
and stained with 2.5 μg/ml calcein-AM at 37 °C for 1 h. Labeled cells were washed
with PBS and measured by flow cytometry (FL2H).
For monitoring cell growth and attachment in real time, the xCELLigence system
(OMNI Life Science, Bremen, Germany) was applied. Melanoma cells were seeded in
special 96-well E-plates (50 000 cells per well), which have microelectrodes
integrated in the bottom of the wells. Continuous measurement of electric resistance
corresponds to attached cell numbers.
MMP and ROS. MMP (Δψm) was determined by staining cells with the
fluorescent dye TMRM+ (Sigma-Aldrich). Cells, grown and treated in 24-well plates,
were harvested by trypsinization and stained for 20 min at 37 °C with 1 μM TMRM+.
After washing two times with PBS, cells were measured by flow cytometry (FL2H).
For determination of intracellular ROS, attached cells in 24-well plates were
preincubated for 1 h with the fluorescent dye H2DCFDA (D-399, Thermo Fisher
Scientific, Hennigsdorf, Germany, 10 μM) before starting treatment with effectors.
After treatment, cells were trypsinized, washed with PBS and analyzed by flow
cytometry (FL1H). As positive control, cells were treated with H2O2 (1 mM, 1 h). For
ROS scavenging, cells were pretreated for 1 h with 1 mM α-tocopherol (vitamin E,
Fluka, Steinheim, Germany).
Western blotting. For Western blotting, total protein extracts were obtained by
cell lysis in 150 mM NaCl, 1 mM EDTA, 2 mM PMSF, 1 mM leupeptin, 1 mM
pepstatin, 0.5% SDS, 0.5% NP-40 and 10 mM Tris-HCl, pH 7.5. Western blotting on
nitrocellulose membranes was performed as described previously.45 Primary
antibodies were: Cleaved caspase-3 (9664, rabbit, 1 : 1000, Cell Signaling,
Danvers, MA, USA), caspase-3 proform (9662, rabbit, 1 : 1000, Cell Signaling),
Mcl-1 (sc-12756, mouse, 1 : 200, Santa Cruz Biotech, Dallas, TX, USA), Bcl-2
(sc-492, rabbit; 1 : 200, Santa Cruz Biotech), Bax (sc-20067, mouse, 1 : 200,
Santa Cruz Biotech), GAPDH (sc-32233, mouse, 1 : 1000, Santa Cruz Biotech),
Puma (ab33906, rabbit, 1 : 1000, Abcam, Cambridge, UK), XIAP (no. 2042, rabbit,
1 : 1000, Cell Signaling), p53 (sc-126, rabbit, 1 : 500, Santa Cruz Biotech), ERK
(no. 4695, rabbit, 1 : 1,000, Cell Signaling), pERK (no. 9101, rabbit, 1 : 1,000, Cell
Signaling), and Bim (no. 559685, rabbit, 1 : 200, BD Biosciences, Heidelberg,
Gemany). Secondary antibodies were: peroxidase-labeled goat anti-rabbit and goat
anti-mouse (Dako, Hamburg, Germany; 1 : 5000).
Statistical analyses. All assays were carried out in triplicate determinations
and at least two independent experiments were performed. Also, Western blotting
data were verified by at least two independent series of cellular extracts. Statistical
significance was proven by Student’s t-test (normal distribution), and P-values of
o0.05 were considered as statistically significant.
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